肌注双价诺如病毒GI.1/GII.4病毒样颗粒疫苗在美国健康成人中的效力
该双盲随机安慰剂对照2b期试验在美国海军新兵中评估TAK-214双价诺如病毒疫苗对中重度急性胃肠炎的效力。结果显示,针对任何诺如病毒基因型所致中重度AGE,疫苗效力为61.8%(95.01%CI 20.8-81.6;p=0.0097),主要针对异型GII.2基因型,提示跨基因型保护。
要点
- TAK-214对任何基因型中重度诺如病毒AGE的VE为61.8%(95.01%CI 20.8-81.6;p=0.0097)。
- 同型GI.1/GII.4中重度AGE主要终点VE为80.0%(99.99%CI -1318.1-99.7;p=0.142),未达统计学显著。
- 疫苗诱导的HBGA阻断抗体升高,且GII.2感染安慰剂病例也出现交叉反应。
核心结论
- TAK-214对任何中重度诺如病毒AGE显示统计学显著效力,主要由异型GII.2基因型驱动,提示跨基因型保护。
研究设计与样本
- 双盲、随机、安慰剂对照2b期试验,两个冬季在美国18-49岁海军新兵中开展。
- 参与者按1:1随机接受肌注生理盐水安慰剂(N=2,357)或TAK-214(15 μg GI.1和50 μg GII.4c VLPs,0.5 mg Al(OH)3)(N=2,355)。
- 接种后监测45天AGE,通过RT-PCR和测序鉴定粪便/呕吐物样本诺如病毒基因型。
主要发现
- 任何严重度诺如病毒AGE共48例,安慰剂组29例、疫苗组19例;基因型为GI.1(n=1)、G1.7a(n=1)、GII.2(n=39)、GII.4(n=7)。
- 任何基因型中重度AGE在安慰剂组26例、疫苗组10例,VE为61.8%(95.01%CI 20.8-81.6;p=0.0097)。
- 同型GI.1/GII.4中重度AGE在安慰剂组5例、疫苗组1例,主要终点VE为80.0%(99.99%CI -1318.1-99.7;p=0.142)。
- 疫苗组及部分感染GII.2的安慰剂AGE病例中GI.1和GII.4 HBGA阻断抗体水平升高,提示不同基因型免疫应答存在交叉反应。
临床怎么用
- TAK-214可能对异型诺如病毒基因型提供交叉保护,但同型效力因病例有限未充分评估。
- 需进一步研究确认疫苗对同型诺如病毒AGE的效力及在更广泛人群中的保护效果。
局限性
- 同型诺如病毒AGE病例有限,主要终点未完全可评估。
- 研究人群为美国海军新兵,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We performed this first-in-human efficacy trial of Takeda's bivalent norovirus vaccine candidate (TAK-214) against moderate or severe acute gastroenteritis (AGE) in healthy adults. METHODS: This double-blind, randomized, placebo-controlled phase 2b trial was conducted over two winter seasons in 18-49 year-old US Navy recruits. Participants were randomized (1:1) to receive intramuscular injections of saline placebo (N = 2,357) or TAK-214 [15 μg GI.1 and 50 μg GII.4c VLPs, 0.5 mg Al(OH)3] (N = 2,355), and monitored for 45 days post-vaccination for AGE. Norovirus genotypes were identified by RT-PCR and sequencing of stool/vomitus samples. Sera from AGE cases were used to assess immune responses as genotype-specific histo-blood group antigen (HBGA)-blocking antibodies. FINDINGS: With low rates of homotypic norovirus AGE detected the statistical analysis was proactively modified to account for AGE due to any norovirus genotype. Of the 48 norovirus AGE cases of "any severity", 29 in placebo and 19 in vaccinees, causative genotypes were GI.1 (n = 1), G1.7a (n = 1), GII.2 (n = 39) and GII.4 (n = 7). Applying predefined definitions of moderate or severe AGE gave 26 vs. 10 cases due to any norovirus genotype in placebo vs. vaccine groups, a vaccine efficacy (VE) of 61.8% (95.01% CI, 20.8 to 81.6; p = 0.0097). Five vs. one moderate or severe cases due to vaccine GI.1/GII.4 homotypic genotypes in placebo vs. vaccine arms gave a primary endpoint vaccine efficacy of 80.0% (99.99% CI, -1318.1 to 99.7; p = 0.142). Levels of GI.1 and GII.4 HBGA-blocking antibodies were increased in vaccinees and in some placebo AGE cases infected with GII.2, indicating cross-reactivity in the immune responses to different genotypes. INTERPRETATION: Despite limited cases of homotypic norovirus AGE meaning the primary endpoint was not fully evaluable, we showed TAK-214 provided statistically significant efficacy against "any moderate/severe norovirus AGE" principally caused by the heterotypic GII.2 genotype, demonstrating induction of cross-genotype protection.
引用
- Sherwood J, Mendelman PM, Lloyd E, et al. Efficacy of an intramuscular bivalent norovirus GI.1/GII.4 virus-like particle vaccine candidate in healthy US adults. Vaccine. 2020. PMID: 32878708. doi:10.1016/j.vaccine.2020.07.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。